Royal Philips

Incorporating some potential obstacles arising from recent Chinese developments

15/09/23 -"Despite Philips gaining confidence, thanks to promising testing results for respiratory devices, improving operations and a big new investor coming on board, our target price resets lower due to ..."

Published on
You may also be interested by these reports :
After a terrible 2022, the situation for MedTechs seemed to be getting better. However, worries again took over, with the sector down c.6% (in ytd ...

We trim our FY23/24 estimates further by a double-digit / low single-digit, respectively, on account of the increasing question marks on the ...

The last time we teased on Sartorius, we believed this high quality bioprocessing asset was still rather expensive even after the 25% drop from its ...

Based on our recent discussion with the Carl Zeiss Meditec, it appears that earnings challenges are set to intensify in the near term due to – ...


Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis


AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO